Skip to main content
Uncategorized

Advancell and researcher Joan Gil win Valdés-Salas award in applied biomedicine

By 15 de June de 2011November 18th, 2020No Comments
< Back to news
 15.06.2011

Advancell and researcher Joan Gil win Valdés-Salas award in applied biomedicine

The head of the research group on apoptosis and cancer of the IDIBELL, and professor of biochemistry and molecular biology at the University of Barcelona, Joan Gil, has been awarded the I Fundación Valdés-Salas Award in Applied Biomedicine. The jury decided unanimously to grant this award to Joan Gil for his research in finding new treatments for leukemia and lymphoma in B cells in collaboration with the company Advancell.


The head of the research group on apoptosis and cancer of the IDIBELL, and professor of biochemistry and molecular biology at the University of Barcelona, Joan Gil, has been awarded the I Fundación Valdés-Salas Award in Applied Biomedicine. The jury decided unanimously to grant this award to Joan Gil for his research in finding new treatments for leukemia and lymphoma in B cells.

The experimental work realized by the group led by Joan Gil in collaboration with the company Advancell has patented the use of Acadesine molecule that has successfully passed all the preclinical stages and led eventually to the development of a clinical trial, currently under course, for the treatment of patients with chronic lymphocytic leukemia. This trial is the first carried out for cancer treatment from a patent generated by a group of the Spanish research public system.

Acadra is the first drug originating from a Spanish public university to reach clinical trials. It was developed from the doctoral thesis work of Clara Campàs, at the Faculty of Pharmacy of the University of Barcelona. Campàs discovered the molecule Acadesine for the treatment of leukemias and lymphomas. In 2003 the University of Barcelona patented the drug through its Patent Center. Clara Campàs, in addition to being the discoverer, was also co-author of the patent for the drug.

The jury highlighted the work of Gil as an example of how a quality basic research, in contrast with scientific publications of considerable prestige, can lead to important practical applications in the field of medicine.

Fundación Valdés-Salas convenes for the first time this award in collaboration with the University of Oviedo and the companies Bayer, Cofas and Farmaindustria. The award aims to recognize the successful collaboration between researchers and companies. The aim is to reward research used by a company with a positive financial result.